These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 37156296

  • 1. The protective role of peroxisome proliferator-activated receptor gamma in lipotoxic podocytes.
    Carrasco AG, Izquierdo-Lahuerta A, Valverde ÁM, Ni L, Flores-Salguero E, Coward RJ, Medina-Gómez G.
    Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Jul; 1868(7):159329. PubMed ID: 37156296
    [Abstract] [Full Text] [Related]

  • 2. Protective effects of PPARγ agonist in acute nephrotic syndrome.
    Zuo Y, Yang HC, Potthoff SA, Najafian B, Kon V, Ma LJ, Fogo AB.
    Nephrol Dial Transplant; 2012 Jan; 27(1):174-81. PubMed ID: 21565943
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis.
    Yang HC, Ma LJ, Ma J, Fogo AB.
    Kidney Int; 2006 May; 69(10):1756-64. PubMed ID: 16598202
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Alternatively Spliced Landscape of PPARγ mRNA in Podocytes Is Distinct from Adipose Tissue.
    Bryant C, Webb A, Banks AS, Chandler D, Govindarajan R, Agrawal S.
    Cells; 2022 Nov 01; 11(21):. PubMed ID: 36359851
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptor ɣ agonist mediated inhibition of heparanase expression reduces proteinuria.
    Garsen M, Buijsers B, Sol M, Gockeln L, Sonneveld R, van Kuppevelt TH, de Graaf M, van den Born J, Kamps JAAM, van Raalte DH, van der Meer RW, Lamb HJ, Hillebrands JL, Rabelink TJ, Maciej-Hulme ML, Krenning G, Nijenhuis T, van der Vlag J.
    EBioMedicine; 2023 Apr 01; 90():104506. PubMed ID: 36889064
    [Abstract] [Full Text] [Related]

  • 7. Zhen-wu-tang protects against podocyte injury in rats with IgA nephropathy via PPARγ/NF-κB pathway.
    Liu B, He Y, Lu R, Zhou J, Bai L, Zhang P, Ye S, Wu J, Liang C, Zhou Y, Zhou J.
    Biomed Pharmacother; 2018 May 01; 101():635-647. PubMed ID: 29518610
    [Abstract] [Full Text] [Related]

  • 8. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.
    Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S, Haugen BR.
    Mol Cancer; 2009 Mar 06; 8():16. PubMed ID: 19267912
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ.
    Zhu C, Huang S, Yuan Y, Ding G, Chen R, Liu B, Yang T, Zhang A.
    Am J Pathol; 2011 May 06; 178(5):2020-31. PubMed ID: 21514419
    [Abstract] [Full Text] [Related]

  • 11. Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells.
    Chen JY, Wang JJ, Lee HC, Chi CW, Lee CH, Hsu YC.
    J Chin Med Assoc; 2020 Oct 06; 83(10):923-930. PubMed ID: 33009242
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
    Sommer M, Wolf G.
    Am J Nephrol; 2007 Oct 06; 27(4):425-34. PubMed ID: 17622750
    [Abstract] [Full Text] [Related]

  • 17. A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers.
    Kotani H, Tanabe H, Mizukami H, Amagaya S, Inoue M.
    Biol Pharm Bull; 2012 Oct 06; 35(1):1-9. PubMed ID: 22223330
    [Abstract] [Full Text] [Related]

  • 18. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
    Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M.
    Endocrinology; 2009 Feb 06; 150(2):862-70. PubMed ID: 19147680
    [Abstract] [Full Text] [Related]

  • 19. The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury.
    Miglio G, Rosa AC, Rattazzi L, Grange C, Collino M, Camussi G, Fantozzi R.
    Br J Pharmacol; 2011 Jan 06; 162(1):111-25. PubMed ID: 20840470
    [Abstract] [Full Text] [Related]

  • 20. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor.
    Dobrian AD.
    Vascul Pharmacol; 2006 Jul 06; 45(1):36-45. PubMed ID: 16716756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.